TCMD: Lymphedema growth offset AffloVest weakness; adjusted EBITDA guidance rose

What happened

Q3 revenue rose 7.1%, with 13% lymphedema growth offsetting AffloVest declines linked to inventory. Full-year revenue guidance was maintained, and adjusted EBITDA guidance was raised to $50 million to $52 million.

Confirmed

Global impact / market context

Rising adjusted EBITDA guidance, which means expected earnings before interest, taxes, depreciation and amortization, signals better expected profit. Lymphedema growth covering AffloVest weakness suggests the company's revenue is becoming less reliant on one product line, supporting future cash available.

Analyst inference

Investors often compare a company's sales growth with its profit guidance. Here, maintained revenue guidance alongside higher profit guidance implies cost control or a richer product mix. The AffloVest inventory issue shows how stocking changes, not just demand, can move reported sales.

Analyst inference

What to watch

1. Watch whether full-year revenue guidance is met while adjusted EBITDA stays within the raised $50 million to $52 million range. Confirmed
2. Company leaders could explain how much AffloVest inventory remains and when reordering might resume, which would clarify whether that sales decline is temporary. Proposed
3. If lymphedema keeps growing faster than the rest of the business, revenue may depend more on that product line, so any slowdown there could hurt sales and profit. Analyst inference

Evidence

• Original source link unavailable